alexa Heterologous Prime-boost Tetravalent Dengue Vaccine Strategy Elicits Complete Protection Against DENV-2 In Non-human Primates
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Chutitorn Ketloy, Eakachai Prompetchara, Poonsook Keelapang, Nopporn Sittisombut and Kiat Ruxrungtham
Chulalongkorn University, Thailand
Chiang Mai University, Thailand
Posters & Accepted Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-058
Dengue is a growing public health problem. Although the first dengue vaccine, the Sanofi CYD-TDV live attenuated vaccine (LAV), was recently licensed, an overall protective efficacy is around 60%. This study provides the proof-of-concept that a new heterologous prime-boost strategy can protect against dengue virus (DENV) challenge in Cynomolgus macaques. By priming with a dengue tetravalent live attenuated vaccine (TLAV) then boosted 2 months later with three times (2-week interval) tetravalent DNA vaccine (TDNA), all vaccinated animals developed neutralizing antibodies against all four dengue serotypes following the first TDNA boost and maintained the constant titers after the second and final boost. As expected, no neutralizing antibody was detected in the negative control animals that received saline and empty plasmid. Both groups of animals were challenged with DENV-2 at one month after the final boost and determined the viremia by real-time PCR. All vaccinated animals exhibited undetectable viral RNA, while negative animals had detectable viral RNA from day 1-9 post-challenge. The presence of viremia post-challenge correlated with >32-fold boost in DENV-2 neutralizing titer at 1 month post-challenge, whereas no >4-fold titer boost was observed in the completely protected animals. Based on these results, we demonstrated the sterilizing protection against the DENV-2 challenge in the heterologous TLAV prime and TDNA boost macaques. Regarding the protective efficacy of a new heterologous TLAV prime-TDNA boost approach, an enlarged experiment to prove the hypothesis by challenging with all dengue serotypes is being conducted.

Chutitorn Ketloy has her expertise in DNA vaccine development and evaluation in both mice and non-human primates. She aims to improve DNA vaccine platform technology and develop immunogens (such as viral like particle) able to prevent dengue virus infection. This is succeeded by optimizing DNA vaccine expression, delivery (needle free injection, in vivo electroporation, and liposome) as well as synergy with other vaccine platform as a prime-boost vaccination.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version